14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026
TPGXL vs NMR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 20, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over TPG Operating Group II, L.P. 6.950% Fixed-Rate Junior Subordinated Notes due 2064 (TPGXL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TPGXL carries a Unified Composite Score of 35.5/100 (SELL) at $20.16 (N/M Forward P/E, 0.0% operating margin), whereas NMR carries 35.0/100 (SELL) at $8.51 (11.4x Forward P/E, 25.1% operating margin).
Defensive Composite Rating Caution: Although NMR compares more favorably head-to-head, both TPGXL (35.5/100 SELL) and NMR (35.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: TPGXL is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 38.3); meanwhile NMR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TPGXL vs NMR. Trailing 12-month operating profitability (TPGXL 0.0% vs NMR 25.1%) and valuation multiples (TPGXL N/M vs NMR 11.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Institutional Equity value chain with N/A market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
NMR Moat ProfileScale & Operating Efficiency Moat
Capital Markets Operator
Competes within the Capital Markets value chain with $26.4B market capitalization and 25.1% operating margin.
OpEx & R&D Reinvestment52.3% of Rev ($7.77B)
90D Engineering Disclosures0 Published
Investor FAQ TPGXL vs NMR Key Questions & Quantitative Answers
As of Nov 20, 2026, Nomura Holdings, Inc (NMR) is the stronger overall head-to-head candidate over TPG Operating Group II, L.P. 6.950% Fixed-Rate Junior Subordinated Notes due 2064 (TPGXL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TPGXL carries a Unified Composite Score of 35.5/100 (SELL) at $20.16 (N/M Forward P/E, 0.0% operating margin), whereas NMR carries 35.0/100 (SELL) at $8.51 (11.4x Forward P/E, 25.1% operating margin). Defensive Composite Rating Caution: Although NMR compares more favorably head-to-head, both TPGXL (35.5/100 SELL) and NMR (35.0/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: TPGXL is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 38.3); meanwhile NMR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
NMR leads the Growth & Scale pillar: TPGXL posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with NMR at +17.9% YoY revenue growth and +13.6% YoY earnings growth on $14.9B TTM revenue (77.4% gross margin, 25.1% operating margin). On trailing 12-month operating scale, TPGXL generates N/A in USD-normalized revenue versus $14.9B for NMR. In operating R&D and SG&A reinvestment, TPGXL deploys N/A (0 90-day corporate R&D disclosures) versus 52.3% of Rev ($7.77B) (0 disclosures) for NMR.
NMR screens cheaper on headline valuation multiples. TPGXL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas NMR trades at 11.4x Forward P/E, 10.4x Trailing P/E, 0.81x PEG, and 1.8x EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TPGXL (0.0% ROE) versus NMR (11.5% ROE) capital efficiency.
In options market volatility and institutional positioning, TPGXL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.36β · 17% Vol realized risk). By comparison, NMR carries 30.7% implied volatility (<1st %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.04β · 34% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.